Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Last trade$0.4044
Day change-$0.0442 (-9.85%)
Day range$0.394 – $0.464
Volume4,584,906
Market cap$125M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$124.95M
Price / earnings
—
Price / book
6.13×
Price / sales
0.63×
EV / sales
0.08×
EV / EBITDA
-0.6×
Profitability
Earnings per share
-$0.16
Return on assets
-13.02%
Return on equity
-218.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.47×
Current ratio
1.36×
Quick ratio
1.24×
Cash ratio
0.98×
Cash flow
Price / cash flow
7.92×
Price / free cash flow
9.01×
Free cash flow
$13.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AKBA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$36.9M
$49.13M
$53.54M
$57.62M
$58.77M
$62.47M
$57.34M
$46.5M
Cost of revenue
$6.36M
$10.42M
$12.29M
$12.54M
$9.38M
$9.92M
$7.63M
$20.37M
Gross profit
$30.54M
$38.7M
$41.25M
$45.09M
$49.38M
$52.55M
$49.71M
$26.13M
Selling, general and administrative
$23.53M
$28.17M
$30.44M
$26.09M
$29.09M
$26.56M
$25.74M
$27.68M
Research and development
$16.18M
$14.06M
$14.81M
$26.65M
$14.94M
$11.01M
$9.75M
$11.79M
Total operating expenses
$42M
$45.03M
$45.95M
$53.64M
$44.93M
$38.46M
$36.2M
$40.44M
Operating income
-$11.46M
-$6.33M
-$4.7M
-$8.55M
$4.45M
$14.09M
$13.51M
-$14.31M
Interest expense
-$3.14M
-$3.07M
$0
$0
-$4.75M
-$6.83M
$0
$0
Income before taxes
-$14.18M
-$8.84M
-$8.93M
-$11.24M
$1.16M
$247K
$6.11M
-$22.8M
Income taxes
$175K
$70K
$126K
$1.01M
$615K
$0
$0
$0
Net income
-$14.35M
-$8.91M
-$9.05M
-$12.24M
$540K
$247K
$6.11M
-$22.8M
Net income attributable to common shareholders
-$14.35M
-$8.91M
-$9.05M
-$12.24M
$540K
$247K
$6.11M
-$22.8M
EBITDA
-$10.02M
-$3.8M
-$4.37M
-$8.23M
$4.77M
$14.41M
$13.83M
-$4.96M
Basic earnings per share
-$0.05
-$0.03
-$0.03
-$0.05
$0.00
$0.00
$0.03
-$0.10
Diluted earnings per share
-$0.05
-$0.03
-$0.03
-$0.05
$0.00
$0.00
$0.03
-$0.10
Recent news
Company coverage with links to the original publishers.
Akebia Therapeutics announced a senior secured term loan facility with Symbiotic Capital consisting of an initial $60 million tranche (fully funded) and up to an additional $80 million available at Symbiotic's discretion. The company used proceeds to fully repay its $55 million BlackRock loan facility. The facility has a 60-month maturity with interest-only payments for 60 months and bears interest at the greater of WSJ Prime plus 4.5% or 11.5%. Akebia reaffirmed its cash runway guidance of at least two years.
The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developments include Phase I initiation of AKB-9090, Phase II trial preparations for LSALT peptide, and anticipated Phase III data from AstraZeneca's ARTEMIS trial in H2 2026.
Akebia Therapeutics announced it will release its Q4 and full year 2025 financial results on February 26, 2026, followed by a conference call at 8:00 a.m. EST to discuss financial results and recent business highlights.
Akebia Therapeutics announced that its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company, focused on kidney disease treatments, will discuss its pipeline outlook including Vafseo prescribing expansion and Praliciguat Phase 2 clinical trial progress.
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.